IDKmonitor® Infliximab Free ADA ELISA K 9650
Sample Type (Matrix): Serum, EDTA Plasma
Sample Volume: 50 µl
Incubation time: 1h 10m
Size: 96 wells
Regulatory Status: Health Canada Licensed.
Kit Manual: Download
The IDKmonitor® Infliximab Free ADA ELISA is intended for the qualitative determination of free human antibodies against Infliximab (e.g. REMICADE®) in EDTA plasma and serum.
Chronic inflammatory diseases like Crohn’s disease, ulcerative colitis, or rheumatoid arthritis are often treated with anti-TNFa antibodies which target directly the underlying inflammatory processes. The clinical efficacy of an anti-TNFa therapy correlates with the trough level of the therapeutic antibody, the drug level just before the next application of the anti-TNFa antibody. Several factors influence the trough level, among them dosage and frequency of anti-TNFa blocker infusion, disease activity, individual pharmacokinetics, and immune reaction (formation anti-drug antibodies, ADA).
It is thought that ADA functionally neutralizes the therapeutic antibodies or induces their rapid elimination. Consequences of ADA formation can be therapy failure and allergic reactions during anti-TNFa antibody application.
In combination with the drug level determination, the IDKmonitor® Infliximab free ADA ELISA can help physicians monitor and optimize therapy early on.
|Dimensions||6.5 × 40 × 4.5 in|